Bengt Anell, Sangeeta Budhia, Richard Macaulay

The five ways pharma developers can get the most out of early engagement with payers and regulators when plotting their clinical and commercial evidence plans.

As regulators lower evidentiary requirements for approval to speed development and review of new drugs for unmet medical needs, payers are demanding more data to justify price premiums. Companies need to be strategic in how they navigate these complexities, write Bengt Anell, Sangeeta Budhia and Richard Macaulay.